The securities purchase agreement will result in an increase in the number of outstanding shares for Biocardia. This may dilute the value of existing shares, but it also provides the company with additional capital. The impact on the stock price is uncertain, as it depends on how the market perceives the agreement and the company's use of the additional funds.